

6 March 2025

Treatment of Renal Cell Carcinoma

Freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions?

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- **Avelumab + Axitinib** <5
- **Axitinib** 0
- **Cabozantinib** 27
- **Everolimus** <5
- **Lenvatinib + Everolimus** 12
- **Lenvatinib + Pembrolizumab** 8
- **Nivolumab monotherapy** 8
- **Nivolumab + Cabozantinib** 29
- **Nivolumab + Ipilimumab** <5
- **Pazopanib** 0
- **Pembrolizumab monotherapy** 21
- **Pembrolizumab + Axitinib** 0
- **Radiotherapy only** 0
- **Sunitinib** <5
- **Temsirolimus** 0
- **Tivozanib** 9
- **Other active systemic anti-cancer therapy** 10
- **Palliative care only** not available

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments?

- **Avelumab + Axitinib (Bavencio + Inlyta)**
- **Cabozantinib (Cometriq)** <5
- **Nivolumab (Opdivo)** 0
- **Nivolumab + Cabozantinib (Opdivo + Cometriq)** <5
- **Nivolumab + Ipilimumab (Opdivo + Yervoy)** <5
- **Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)** <5

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- **Nivolumab (monotherapy)** 0

6 March 2025

- **Nivolumab + Ipilimumab** <5
- **Nivolumab + Cabozantinib** <5
- **Avelumab + Axitinib** <5
- **Lenvatinib + Pembrolizumab (Kisplyx + Keytruda)** <5
- **Cabozantinib (Cometriq)** <5

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Belfast Trust show in the last 3 months (December to February), 4 patient's underwent a full Nephrectomy (if excluding Nephroureterectomy), and 24 patient's had a partial Nephrectomy.

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

Yes - **ModiFY** - A Phase 1/2 Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer
Belfast Trust Recruitment 17.02.2026: <5

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.